AR099385A1 - Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona - Google Patents

Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona

Info

Publication number
AR099385A1
AR099385A1 ARP150100093A ARP150100093A AR099385A1 AR 099385 A1 AR099385 A1 AR 099385A1 AR P150100093 A ARP150100093 A AR P150100093A AR P150100093 A ARP150100093 A AR P150100093A AR 099385 A1 AR099385 A1 AR 099385A1
Authority
AR
Argentina
Prior art keywords
composition
quinazolin
oxo
amino
weight
Prior art date
Application number
ARP150100093A
Other languages
English (en)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR099385A1 publication Critical patent/AR099385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan en la presente memoria composiciones farmacéuticas y formas de dosificación unitarias individuales de 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidina-2,6-diona, o un estereoisómero, profármaco, sal, solvato, hidrato o clatrato aceptable para uso farmacéutico. También se proporcionan métodos para el tratamiento, control o prevención de diversos trastornos, tales como un cáncer, una enfermedad inflamatoria y/o un trastorno inmunológico. Reivindicación 1: Una forma de dosificación oral en la forma de una cápsula que comprende: 1) el Compuesto A en una cantidad de aproximadamente 0,5 a aproximadamente 3 por ciento en peso del peso total de la composición; 2) un ligante o relleno en una cantidad de aproximadamente 90 a 96 por ciento en peso del peso total de la composición, en la que el ligante o relleno es lactosa, celulosa microcristalina silicificada, o una mezcla de las mismas, en la que el compuesto A es 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidina-2,6-diona. Reivindicación 2: La forma de dosificación oral de la reivindicación 1, que además comprende un disgregante en una cantidad de aproximadamente 1 a 5 por ciento en peso del peso total de la composición. Reivindicación 3: La forma de dosificación oral de la reivindicación 2, en la que el disgregante es croscarmelosa de sodio. Reivindicación 5: La composición oral de la reivindicación 4, en la que el lubricante es estearato de magnesio.
ARP150100093A 2014-01-15 2015-01-14 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona AR099385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461927895P 2014-01-15 2014-01-15

Publications (1)

Publication Number Publication Date
AR099385A1 true AR099385A1 (es) 2016-07-20

Family

ID=52444635

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100093A AR099385A1 (es) 2014-01-15 2015-01-14 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona

Country Status (4)

Country Link
US (1) US20150196562A1 (es)
AR (1) AR099385A1 (es)
TW (1) TW201540323A (es)
WO (1) WO2015108889A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2428513T3 (en) 2006-09-26 2017-08-21 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
SG192946A1 (en) 2011-03-11 2013-09-30 Celgene Corp Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CN104755472A (zh) 2012-09-04 2015-07-01 细胞基因公司 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
EA201890585A1 (ru) 2015-08-27 2018-11-30 Селджин Корпорейшн Составы 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
CA3006758A1 (en) 2015-12-02 2017-06-08 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
EP3644999B1 (en) * 2017-06-30 2022-12-14 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
EP3735243A4 (en) * 2018-01-02 2021-08-25 Celgene Corporation ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
AU2002343220A1 (en) 2001-11-09 2003-05-19 Matsushita Electric Industrial Co., Ltd. Moving picture coding method and apparatus
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
JP2007530544A (ja) 2004-03-22 2007-11-01 セルジーン・コーポレーション 皮膚疾患又は障害を治療及び管理するための免疫調節化合物の使用方法及びそれを含む組成物
JP2007533761A (ja) 2004-04-23 2007-11-22 セルジーン・コーポレーション 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物
EP1814543A2 (en) 2004-11-12 2007-08-08 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
WO2006058008A1 (en) 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
DK2428513T3 (en) 2006-09-26 2017-08-21 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
EP2683384B1 (en) * 2011-03-11 2015-12-09 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
SG192946A1 (en) * 2011-03-11 2013-09-30 Celgene Corp Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2012149299A2 (en) * 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
CA2935495C (en) * 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives

Also Published As

Publication number Publication date
US20150196562A1 (en) 2015-07-16
TW201540323A (zh) 2015-11-01
WO2015108889A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
AR099385A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
PE20160550A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
DOP2016000156A (es) Composiciones farmacã¿uticas que comprenden azd9291.
SA517381749B1 (ar) صيغ من 2-(تيرت-بيوتيل أمينو)-4-((1r،3r،4r)-3-هيدروكسي-4-ميثيل سيكلو هكسيل أمينو)-بيريميدين-5-كربوكساميد
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
JP2017061576A5 (es)
UA117154C2 (uk) Антагоністи s1p3
CO2017011020A2 (es) Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k)
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PE20151607A1 (es) Formulaciones de compuestos organicos
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
TN2015000524A1 (en) Pharmaceutical compositions
BR112019006588A2 (pt) composição farmacêutica de liberação imediata
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
BR112018072371A2 (pt) uso de manitol, composição farmacêutica ou uso, método para preparar uma forma de dosagem sólida compreendendo tibolona

Legal Events

Date Code Title Description
FB Suspension of granting procedure